Spyre Therapeutics(SYRE) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update Continued execution towards expected milestones across portfolio, with SPY001 on-track for interim Phase 1 data by year-end 2024, and SPY002 on-track for initiation of first-in-human trials in the fourth quarter of 2024 Presented new data on SPY003, a potential best-in-class half-life extended anti-IL-23 antibody, demonstrating robust preclinical potency and a greater than three-fold increase in non-hu ...